4//SEC Filing
Luly Jay R. 4
Accession 0001062993-25-002225
CIK 0001177648other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 8:09 PM ET
Size
5.6 KB
Accession
0001062993-25-002225
Insider Transaction Report
Form 4
Luly Jay R.
DirectorPresident and CEO
Transactions
- Purchase
Common Stock
2025-02-12$5.69/sh+45,000$256,050→ 846,638 total
Footnotes (2)
- [F1]The reporting person's purchase of common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 5,142 shares, all of which related to a "sell to cover" transaction required to satisfy tax withholding obligations due as a result of settlement of a portion of a restricted stock unit award granted on November 23, 2022. The reporting person has paid to Enanta $13,861.92, representing the full amount of the profit realized in connection with the short-swing transaction.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $5.32 to $5.86, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote of this Form 4.
Issuer
ENANTA PHARMACEUTICALS INC
CIK 0001177648
Entity typeother
Related Parties
1- filerCIK 0001571211
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 8:09 PM ET
- Size
- 5.6 KB